Monika Engelhardt

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Strength and muscle mass loss with aging process. Age and strength loss

Karsten Keller, Monika Engelhardt · Muscles Ligaments and Tendons Journal · 2019 · 504 citations · Full text

Medicine, Geriatric Medicine, Aging +16

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Evangelos Terpos, Martina Kleber, Monika Engelhardt et al. · Haematologica · 2015 · 398 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 327 citations

Medicine, Hematology, Oncology +14